The effect of casirivimab with imdevimab on disease progression in nonsevere COVID‐19 patients in a single hospital in Japan

BACKGROUND: Recent randomized trials have revealed that neutralizing monoclonal antibodies can reduce disease progression in mild–moderate COVID‐19 patients. However, no studies have investigated the effect of neutralizing monoclonal antibodies on clinical outcomes in Japan. METHODS: A single‐center...

Descripción completa

Detalles Bibliográficos
Autores principales: Komagamine, Junpei, Yabuki, Taku, Yoshihara, Satsuki, Tanaka, Nao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062551/
https://www.ncbi.nlm.nih.gov/pubmed/35509339
http://dx.doi.org/10.1002/jgf2.516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062551/
https://www.ncbi.nlm.nih.gov/pubmed/35509339
http://dx.doi.org/10.1002/jgf2.516

Ejemplares similares